Disclosures: Peter H Hwang, MD Nothing to disclose. Zara M Patel, MD Nothing to disclose. Daniel G Deschler, MD, FACS Nothing to disclose. Stephen B Calderwood, MD Patent Holder: Vaccine Technologies Inc. [Vaccines (Cholera vaccines)]. Equity Ownership/Stock Options: Pulmatrix [Inhaled antimicrobials]; PharmAthene [Anthrax (Anti-protective antigen monoclonal antibody)]. Lee Park, MD, MPH Employment (Spouse): Novartis [Age-related macular degeneration (ranibizumab)].
Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence.
INTRODUCTION — Acute rhinosinusitis (ARS) is defined as symptomatic inflammation of the nasal cavity and paranasal sinuses lasting less than four weeks. The term "rhinosinusitis" is preferred to "sinusitis" since inflammation of the sinuses rarely occurs without concurrent inflammation of the nasal mucosa .
The most common etiology of ARS is a viral infection associated with the common cold. Viral rhinosinusitis is complicated by acute bacterial infection in only 0.5 to 2.0 percent of episodes . Uncomplicated acute viral rhinosinusitis (AVRS) typically resolves in 7 to 10 days. Acute bacterial rhinosinusitis (ABRS) may also be a self-limited disease. Rarely, patients with untreated bacterial disease may develop serious complications. (See "Orbital cellulitis".)
This topic will address the treatment of acute rhinosinusitis. The clinical manifestations and diagnosis of acute rhinosinusitis are discussed separately. (See "Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis".)
APPROACH TO TREATMENT — The goals of treatment for acute rhinosinusitis (ARS) are different, depending on whether the source of infection is viral or bacterial. Distinguishing viral from bacterial ARS is discussed separately. (See "Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis", section on 'Distinguishing bacterial from viral infection'.)
AVRS is expected to resolve within 10 days. ABRS may also resolve spontaneously within the first 10 days. Patients who present with fewer than 10 days of symptoms, in the absence of high fever or symptoms suggesting complicated illness, should be managed with supportive care . Management of acute viral rhinosinusitis (AVRS) aims to relieve symptoms of nasal obstruction and rhinorrhea; treatment does not shorten the clinical course of the disease. (See 'Symptomatic therapy for acute rhinosinusitis' below.)
Treatment options for ABRS include watchful waiting or antibiotics. Decisions regarding treatment are made based on severity of illness and the availability of patients for follow up. (See 'Community-acquired acute bacterial rhinosinusitis' below.)
SYMPTOMATIC THERAPY FOR ACUTE RHINOSINUSITIS — Symptomatic therapy is indicated for both acute viral rhinosinusitis (AVRS) and acute bacterial rhinosinusitis (ABRS).
Analgesics — Analgesics such as nonsteroidal anti-inflammatories and acetaminophen are used for pain relief.
Saline irrigation — Mechanical irrigation with buffered, physiologic, or hypertonic saline may reduce the need for pain medication and improve overall patient comfort, particularly in patients with frequent sinus infections. The evidence supporting use of saline irrigation is limited, but indicates possible benefits for symptom relief with minor adverse effects, including nasal burning and irritation . It is important that irrigants be prepared from sterile or bottled water, as there have been reports of amebic encephalitis due to tap water rinses . Instructions for preparing a rinse solution are shown in a table (table 1).
Intranasal glucocorticoids — The theoretic mechanism of action for intranasal glucocorticoids (corticosteroids) is a decrease in mucosal inflammation that allows improved sinus drainage. Studies evaluating topical glucocorticoids should be interpreted with caution, as many studies contain both heterogeneous patient populations (acute, chronic, and/or viral rhinosinusitis) and different treatment regimens (concomitant decongestant, saline irrigation, antibiotic).
Studies of intranasal glucocorticoids have demonstrated some benefit for the relief of symptoms in ARS, both viral and bacterial. A meta-analysis of three studies, involving patients with ARS diagnosed by symptoms and confirmed by radiologic or endoscopic studies, found that use of intranasal steroids, alone or as adjuvant therapy to antibiotics, increased the rate of symptom response compared to placebo (RR 1.11, 95% CI 1.04-1.18) . Symptom resolution was greater for patients receiving intranasal glucocorticoids than placebo, and a dose response was observed, comparing mometasone furoate 200 and 400 mcg. When used as an adjunct to antibiotic therapy in the treatment of ABRS, a meta-analysis of placebo-controlled trials suggests that 15 patients would need to be treated with intranasal glucocorticoids to improve clinical symptoms in one patient . One randomized study of patients with ABRS did not demonstrate benefit for intranasal glucocorticoids . Subgroup analysis of this study, however, found that patients with less-severe symptoms did benefit, possibly because thicker nasal secretions and closed ostia in patients with more severe illness limit penetrance of the topical steroids.
Intranasal glucocorticoids are likely to be most beneficial for patients with underlying allergic rhinitis.
Intranasal decongestants — The use of intranasal decongestants, such as oxymetazoline, may provide a subjective sense of improved nasal patency. However, there is some concern that intranasal decongestants themselves may provoke mucosal inflammation, at least in an experimental animal model . If used, topical decongestants should be used sparingly (no more than three consecutive days) to avoid rebound congestion . Topical decongestants are an option for symptomatic relief in the treatment of AVRS . However, they have little effect as adjunctive therapy to antibiotics in the treatment of ABRS [7,11].
Oral decongestants — Oral decongestants are frequently used to reduce edema and facilitate aeration and drainage. Consistent reports on their efficacy are lacking, however. Some [12,13], but not all , studies have demonstrated improved patency of the nasal airway and sinus ostia. One randomized trial compared several oral decongestants (ephedrine sulfate 25 mg, pseudoephedrine HCL 60 mg, phenylephrine HCL 10 mg, and phenylpropanolamine HCL 25 mg) with placebo; only ephedrine was superior to placebo in this trial . Similar to their recommendations against topical formulations, 2012 guidelines advise that oral decongestants are not helpful in patients with ABRS .
When eustachian tube dysfunction is a significant confounding factor in AVRS, a short course (three to five days) of oral decongestants may be warranted. Oral decongestants should be used with caution in patients with cardiovascular disease, hypertension, or benign prostate hypertrophy due to systemic adverse effects with oral alpha adrenergic preparations .
Antihistamines — Antihistamines are frequently prescribed for symptom relief due to their drying effects; however, there are no studies investigating their efficacy for this indication . Additionally, over-drying of the mucosa may lead to further discomfort. Antihistamines have side effects (drowsiness, xerostomia), and their use for the treatment of acute sinusitis is not recommended .
COMMUNITY-ACQUIRED ACUTE BACTERIAL RHINOSINUSITIS — For patients who present with 10 or more days of symptoms (purulent rhinorrhea, nasal congestion, and facial pressure), the likelihood of a diagnosis of ABRS is increased. An algorithm for the treatment of acute bacterial rhinosinusitis is shown (algorithm 1). (See "Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis", section on 'Distinguishing bacterial from viral infection' and 'Approach to treatment' above.)
Observation — Observation (watchful waiting) is an option for patients with uncomplicated ABRS who have good follow-up . Antibiotics should be initiated in patients without improvement or worsening. Guidelines differ in as to when to start antibiotics if there is no improvement in symptoms.
Guidelines from a multidisciplinary expert panel in 2015 recommend that selected patients with symptoms suggestive of uncomplicated ABRS (temperature <38.3°C or 101°F and no extra-sinus complications) may be managed expectantly without antibiotics . Patients under observation should be treated supportively for relief of symptoms for 7 to 10 days after the time of diagnosis. If there is no improvement over this interval, or if there is worsening at any time, antimicrobial therapy should be initiated. Guidelines from the Infectious Disease Society of America (IDSA) in 2012 recommend that antimicrobial therapy might be withheld for three days in patients with mild symptoms, but initiated promptly thereafter if there is no improvement . Factors such as age, general state of health, and comorbidities should be considered when choosing this option.
Studies suggest that 40 to 69 percent of patients with ABRS may clear their infection spontaneously [17-19]. In most of these studies, however, the diagnosis of acute bacterial infection was not confirmed by sinus aspirate culture, but rather was based upon clinical criteria. The populations studied were therefore likely to include patients with viral infection. Thus, the actual rate of spontaneous resolution of bacterial infection is not certain, but likely to be lower than the reported 40 to 60 percent. In a 2012 systematic review of 10 trials involving patients with uncomplicated acute sinusitis and a normal immune system, antibiotics slightly shortened the time to cure (number needed to treat for benefit 18) but increased the incidence of adverse effects (number needed to treat for harm 8) . Almost 50 percent of patients improved by one week, and 70 percent by two weeks, irrespective of whether they had received antibiotics or not.
Antimicrobials — Patients who are initially managed with observation but fail to improve or worsen and patients with severe symptoms who meet clinical criteria for ABRS regardless of duration of illness should be treated with an antibiotic (algorithm 1) .For patients with severe symptoms, the rationale is to shorten the duration of illness, relieve symptoms, and prevent recurrent infection or complications, such as orbital cellulitis. (See "Orbital cellulitis".)
Several studies and meta-analyses have addressed the efficacy of systemic antibiotics in the treatment of acute rhinosinusitis (ARS). Given the difficulty in distinguishing viral from bacterial infection, these studies are complicated by heterogeneity in patient symptoms, underlying etiology, and outcomes of treatment.
●A randomized trial of adult patients (n = 166) presenting to primary care offices who met clinical criteria for acute bacterial rhinosinusitis (ABRS) evaluated whether a 10-day course of amoxicillin, compared to placebo, improved disease-related quality of life as measured by a symptom score . There was no difference between groups at day 3, the primary specified outcome, or at day 10, although there was greater symptom improvement reported by the amoxicillin group at day 7. All patients were also offered symptomatic treatment for relief of pain, fever, cough, and nasal congestion.
●A 2008 meta-analysis based upon individual patient data (n = 2547) from nine randomized trials found that 15 patients with rhinosinusitis would need to be treated with antibiotics before one additional patient would be cured . Clinical signs and symptoms did not define a patient subgroup that was more likely to benefit from treatment or distinguish viral from bacterial infection.
●A 2012 meta-analysis of 13 randomized trials in adults with ABRS (n = 2878) found that 13 patients (95% CI 9-22) would need to be treated with antibiotics for one to benefit .
●A 2008 meta-analysis pooled results from 17 randomized trials in which acute sinusitis was variably diagnosed (the majority by clinical criteria, but also imaging, microbiology, and inflammatory markers) . There was variability in choice of antibiotic, use of ancillary therapy, and inclusion of children (three studies). Compared to placebo, antibiotics were associated with a higher rate of cure or symptom improvement at 7 to 15 days (OR 1.64, 95% CI 1.35-2.0), but the magnitude of effect was moderate (cure or improvement in 77 percent with antibiotics versus 68 percent with placebo). The 9 percent difference in cure/improvement rate with antibiotic therapy was at the expense of an 8 percent increase in adverse effects, mostly gastrointestinal (30 versus 22 percent for placebo-treated patients).
●A meta-analysis that analyzed data from five trials comparing antibiotics to placebo, defining failure as lack of cure or improvement at 7 to 15 days follow-up, found an increased response rate for antibiotics (RR 0.66, 95% CI 0.44-0.98) . Eighty percent of the participants not treated with antibiotics and 90 percent of the antibiotic group improved within two weeks. No one antibiotic was superior to another in the review of 51 studies comparing antibiotics.
Choice of antibiotic — When antibiotics are administered, treatment is most often initiated empirically. Although culture-guided therapy is optimal, obtaining suitable cultures requires endoscopy or antral puncture and is generally reserved for patients with complications. (See "Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis", section on 'Diagnostic tests'.)
Most comparative studies of antibiotics for the treatment of ABRS do not involve patients with culture-defined infection and therefore include patients who meet predefined clinical criteria but who may not have bacterial infection. The significant rate of spontaneous recovery in mixed populations of AVRS and ABRS decreases the ability of studies to differentiate between less-effective and more-effective antibiotics (the apparent response to less-effective antibiotics is greater than would be seen in a more strictly defined ABRS population; conversely, the relative effectiveness of more appropriate antibiotics is diminished). Thus, the finding in multiple studies of equivalent effectiveness among antibiotics is called into some question [19,23-27].
Amoxicillin has been recommended as a first-line agent in the past because of its narrow spectrum and relative low cost. However, there is increasing emergence of antimicrobial resistance among respiratory pathogens, including pneumococci and H. influenzae. Resistance rates vary regionally, with the prevalence of H. influenzae resistance ranging from 27 to 43 percent in the US . Additionally, the introduction of routine conjugated pneumococcal vaccination in children has changed the spectrum of bacterial infection. In both adults and children, the percentage of ABRS due to S. pneumoniae has decreased while the proportion of ABRS due to H. influenzae has increased.
The addition of clavulanate to amoxicillin improves coverage for ampicillin-resistant H. influenzae as well as M. catarrhalis. While evidence is stronger in children than adults to support use of amoxicillin-clavulanate instead of amoxicillin, the IDSA 2012 guidelines makes the following recommendations regarding antimicrobial treatment of ABRS in adults :
●Amoxicillin-clavulanate rather than amoxicillin is recommended as empiric therapy for non-penicillin allergic adults. Amoxicillin-clavulanate is also preferred to a respiratory fluoroquinolone as initial empiric therapy. The dose of amoxicillin-clavulanate for most patients would be either 500 mg/125 mg orally three times daily or 875 mg/125 mg orally twice daily.
●High-dose amoxicillin-clavulanate (2 g orally twice daily) is recommended in geographic regions with rates of penicillin-nonsusceptible S. pneumonia exceeding 10 percent and for patients who meet any of the following criteria: 65 years and older, recently hospitalized, treated with an antibiotic in the previous month, or immunocompromised.
●Doxycycline is a reasonable alternative for first-line therapy and can be used in patients with penicillin allergy. A respiratory fluoroquinolone (levofloxacin or moxifloxacin) is another option for penicillin-allergic patients.
●Macrolides (clarithromycin or azithromycin), trimethoprim-sulfamethoxazole, and second- or third-generation cephalosporins are not recommended for empiric therapy because of high rates of resistance of S. pneumoniae (and of H. influenzae for trimethoprim-sulfamethoxazole).
●Routine coverage for S. aureus or methicillin-resistant S. aureus (MRSA) is not indicated at this time. Despite the prevalence of staphylococcal colonization in the middle meatus in health adults, S. aureus remains an uncommon cause of ABRS .
Local and regional histograms of bacterial resistance should be referenced to understand resistance trends in the local community.
The recommendation to treat with amoxicillin-clavulanate rather than a respiratory fluoroquinolone is based upon studies showing equivalent effectiveness in patients with culture-documented infection  and a need to limit the overuse of fluoroquinolones in an effort to slow the development of resistance to this antibiotic class.
Pregnant patients can be treated with amoxicillin-clavulanate (class B); pregnant patients who are penicillin-allergic would need to be treated with azithromycin (class B), as doxycycline (class D) and fluoroquinolones (class C) are not options in pregnancy.
Duration for initial treatment — The IDSA guidelines advise a 5 to 7 day course of antibiotics (rather than 10 to 14 days) in adults. In one meta-analysis of 12 randomized trials of ABRS in adults, no difference was noted in response rates or relapse rates comparing short courses (3 to 7 days) and longer courses (6 to 10 days) of antibiotics . Rates of adverse events were lower for 5 day compared with 10 day courses. However, there was heterogeneity in the trials in terms of symptom duration and use of adjunctive medications. Studies of antimicrobial response, based upon sinus aspirate cultures in children, indicate bacterial eradication within 72 hours for appropriate antimicrobial treatment , supporting a shorter antibiotic course than has traditionally been advised.
Systemic glucocorticoids — We suggest not using systemic glucocorticoids in the outpatient treatment of acute rhinosinusitis pending the availability of additional data from higher-quality trials. When given in addition to antibiotics, oral glucocorticoids may shorten the time to symptom resolution or improvement. However, the benefits are small and unlike topical glucocorticoids, systemic glucocorticoids possess a significant side effect profile. (See "Major side effects of systemic glucocorticoids".)
A 2014 systematic review and meta-analysis evaluated five randomized trials in adults with acute sinusitis (n = 1193). Four trials evaluated the benefits of glucocorticoids in addition to antibiotics (three trials compared antibiotics and glucocorticoids with antibiotics and placebo, one trial compared antibiotics and glucocorticoids with antibiotics and a nonsteroidal anti-inflammatory). One trial compared systemic glucocorticoids with placebo. Patients receiving steroids were more likely to have resolution or improvement in symptoms at 3 to 7 days (RR 1.3, 95%CI 1.1-1.6) . Another 2015 systematic review and meta-analysis included only the four trials where antibiotics were prescribed and had similar results (improved symptom control at three to seven days with steroids, RR 1.4, 95% CI 1.1-1.8). These data are limited by the potential for attrition bias and the lack of long-term follow-up on the effects of steroids . Furthermore, in a randomized trial, oral prednisolone 30 mg daily for seven days was not more effective than placebo in reducing facial pain or pressure on day seven for adult patients with clinically diagnosed acute rhinosinusitis .
Treatment failure — Patients with ABRS are expected to show some response to empiric antimicrobial therapy after three to five days. An alternative treatment strategy is indicated for patients with ABRS who fail to show some improvement in that time frame, or in whom symptoms worsen after at least two to three days of therapy. Experimental evidence indicates bacterial eradication by day three [35,36] and studies have correlated clinical and bacteriologic response . Although older adults or those with multiple comorbidities may take longer to resolve infection, such individuals should also show some symptom improvement within five days of initiating antimicrobial therapy for ABRS .
Reasons for treatment failure include resistant pathogens, inadequate dosing, structural abnormalities, or a noninfectious etiology. Patients who fail first-line therapy require alternative antibiotic selection. Ideally, an endoscopically-guided culture could be performed to redirect antibiotic therapy, although this is often impractical. Options for second-line therapy provide a broader spectrum of activity and/or a different class of agent.
Guidelines from the IDSA recommend the following options for empiric second-line treatment. If improvement is seen within 3 to 5 days of initiation of therapy, a total course duration of 7 to 10 days is recommended:
●Amoxicillin-clavulanate 2000 mg/125 mg orally twice daily
●Levofloxacin 500 mg orally once daily
●Moxifloxacin 400 mg orally once daily
Patients with severe infection requiring hospitalization could be treated with one of the following: a respiratory fluoroquinolone (levofloxacin or moxifloxacin in doses above, either orally or intravenously) or intravenous ampicillin-sulbactam 1.5 to 3.0 g every six hours, ceftriaxone 1 to 2 g every 24 hours, or cefotaxime 2 g every four to six hours. Although specific recommendations from the IDSA are not available, we suggest that intravenous antibiotics be given until there is clear evidence of patient response, at which time the patient could be discharged on an oral antibiotic with similar activity to complete a 10-day course. If there is no response to intravenous antibiotics within 48 hours of hospitalization, a CT scan should be performed to verify the diagnosis and to evaluate for suppurative complications (eg, orbital cellulitis, intracranial abscess) and an ENT consultation requested to obtain sinus cultures and for consideration of the need for surgical intervention.
A CT scan of the sinuses is indicated if symptoms worsen or fail to improve. For patients who have failed to respond to both first- and second-line therapy, sinus cultures should be obtained either by direct aspirate or endoscopy of the middle meatus; nasopharyngeal cultures are not reliable.
Relapse after treatment — Recurrence of symptoms within two weeks of response to initial treatment usually represents inadequate eradication of infection. Patients who had a good response to initial therapy and who have mild symptoms of relapse can be treated with a longer course of the same antibiotic. Patients who had only minimal symptom response with the initial antibiotic or whose relapse is moderate to severe, however, are more likely to have organisms resistant to the initial empiric antibiotic and would require a change in the drug selected. The recommended duration of antibiotic treatment for relapse has not been addressed by published guidelines. The treatment duration should be guided by the goal of full resolution of symptoms. If symptoms persist despite a repeat 7- to 10-day course of antibiotics, referral to an otolaryngologist is warranted. (See 'Treatment failure' above.)
INDICATIONS FOR SPECIALTY REFERRAL — Early referral is essential for patients whose symptoms indicate the need for urgent endoscopy or surgical biopsy, or for diagnostic testing (imaging or immunologic testing) that couldn’t be performed where they have initially presented. Such patients include those with severe infection (high persistent fever, orbital edema, severe headache, visual disturbance, altered mental status, or meningeal signs), those in whom fungal sinusitis or granulomatous disease is suspected, and those with nosocomial infection.
Patients with identified anatomic defects causing obstruction require referral for surgery. Patients who are immunocompromised or are found to have unusual or resistant pathogens might benefit from consultation with an infectious disease specialist. Additionally, referral is indicated for patients with ABRS who have failed to respond to first- and second-line antimicrobial therapy.
Guidelines have developed consensus recommendations about indications for less-urgent specialty referral as follows [7,11]:
●Multiple recurrent episodes of ABRS (three to four episodes per year)
●Chronic rhinosinusitis (with or without polyps or asthma) with recurrent exacerbations of ABRS
●Patients with allergic rhinitis who may be candidates for immunotherapy
SURGERY — There is no indication for surgery in patients with uncomplicated ABRS. However, surgery may be emergently indicated in patients experiencing extra-sinus complications of ABRS, including orbital abscess, epidural abscess, meningitis, and brain abscess. Surgical debridement is also indicated for the treatment of acute invasive fungal rhinosinusitis, a condition for which mortality rates remain high despite timely debridement and systemic antifungal therapy. (See "Fungal rhinosinusitis".)
Indications for surgery in patients with chronic rhinosinusitis are discussed separately. (See "Management of chronic rhinosinusitis", section on 'Indications for surgery'.)
INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)
●Beyond the basics topics (see "Patient information: Acute sinusitis (sinus infection) (Beyond the Basics)")
SUMMARY AND RECOMMENDATIONS
●AVRS is expected to resolve within 10 days; ABRS may also resolve spontaneously within the first 10 days. Patients who present with fewer than 10 days of symptoms, in the absence of high fever or symptoms suggesting complicated illness, should be managed with supportive care. We suggest mild analgesics, saline nasal irrigation, and fluid (Grade 2C). We suggest treatment with intranasal glucocorticoids (Grade 2B). Decongestants may be useful when eustachian tube dysfunction is a factor for patients with AVRS, but are not likely to be helpful for patients with ABRS and have adverse side effects. We suggest not treating symptoms with antihistamines (Grade 2C). (See 'Symptomatic therapy for acute rhinosinusitis' above.)
●Observation (watchful waiting) is an option for patients with uncomplicated ABRS who have good follow-up. Antibiotics should be initiated in patients without improvement or worsening. (See 'Observation' above.)
●We recommend treatment with an antibiotic for patients whose clinical symptoms meet criteria for ABRS and have either severe symptoms or symptoms suggesting complicated illness (algorithm 1) (Grade 1B). Antibiotics should also be started in patients managed with observation but without improvement or worsening of symptoms. In light of increasing microbial resistance to antibiotics, we suggest initial empiric treatment with amoxicillin-clavulanate rather than macrolides (clarithromycin or azithromycin), trimethoprim-sulfamethoxazole, or oral second- or third-generation cephalosporins (Grade 2B). For most patients, amoxicillin-clavulanate (either 500 mg/125 mg orally three times daily or 875 mg/125 mg orally twice daily) should be given for five to seven days. Doxycycline is a reasonable alternative for first-line therapy and can be used in patients with penicillin allergy. A respiratory fluoroquinolone (levofloxacin or moxifloxacin) is another option for penicillin-allergic patients. (See 'Choice of antibiotic' above and 'Duration for initial treatment' above.)
●Local and regional histograms of bacterial resistance should be referenced to understand resistance trends in the local community. (See 'Choice of antibiotic' above.)
●Patients with ABRS are expected to show some response to empiric antimicrobial therapy after three to five days. An alternative treatment strategy is indicated for patients with ABRS who fail to show some improvement in that time frame, or in whom symptoms worsen after at least two to three days of therapy. Options for second-line empiric therapy include high-dose amoxicillin-clavulanate (2000 mg/125 mg orally twice daily) or a respiratory fluoroquinolone (levofloxacin 500 mg orally once daily or moxifloxacin 400 mg orally once daily). (See 'Treatment failure' above.)
●Specialty referral on an urgent basis is indicated for patients with severe infection (high persistent fever, orbital edema, severe headache, visual disturbance, altered mental status, or meningeal signs), those in whom fungal sinusitis or granulomatous disease is suspected, and those with nosocomial infection. Referral is also indicated for patients with obstructive anatomic defects, immunocompromise, resistant pathogens, or failure to respond to first- and second-line antimicrobial therapy. (See 'Indications for specialty referral' above.)
●There is no indication for surgery in patients with uncomplicated ABRS. However, surgery may be emergently indicated in patients experiencing extra-sinus complications of ABRS, including orbital abscess, epidural abscess, meningitis, and brain abscess. (See 'Surgery' above.)
ACKNOWLEDGMENT — The editorial staff at UpToDate would like to acknowledge Anne Getz, MD, who contributed to an earlier version of this topic review.
- Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: Establishing definitions for clinical research and patient care. Otolaryngol Head Neck Surg 2004; 131:S1.
- Fokkens W, Lund V, Mullol J, European Position Paper on Rhinosinusitis and Nasal Polyps Group. EP3OS 2007: European position paper on rhinosinusitis and nasal polyps 2007. A summary for otorhinolaryngologists. Rhinology 2007; 45:97.
- Tan T, Little P, Stokes T, Guideline Development Group. Antibiotic prescribing for self limiting respiratory tract infections in primary care: summary of NICE guidance. BMJ 2008; 337:a437.
- King D, Mitchell B, Williams CP, Spurling GK. Saline nasal irrigation for acute upper respiratory tract infections. Cochrane Database Syst Rev 2015; 4:CD006821.
- Louisiana Department of Health and Hospitals. http://new.dhh.louisiana.gov/index.cfm/newsroom/detail/2332 (Accessed on January 22, 2012).
- Zalmanovici Trestioreanu A, Yaphe J. Intranasal steroids for acute sinusitis. Cochrane Database Syst Rev 2013; 12:CD005149.
- Chow AW, Benninger MS, Brook I, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis 2012; 54:e72.
- Williamson IG, Rumsby K, Benge S, et al. Antibiotics and topical nasal steroid for treatment of acute maxillary sinusitis: a randomized controlled trial. JAMA 2007; 298:2487.
- Bende M, Fukami M, Arfors KE, et al. Effect of oxymetazoline nose drops on acute sinusitis in the rabbit. Ann Otol Rhinol Laryngol 1996; 105:222.
- Spector SL, Bernstein IL, Li JT, et al. Parameters for the diagnosis and management of sinusitis. J Allergy Clin Immunol 1998; 102:S107.
- Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg 2015; 152:S1.
- Roth RP, Cantekin EI, Bluestone CD, et al. Nasal decongestant activity of pseudoephedrine. Ann Otol Rhinol Laryngol 1977; 86:235.
- Melén I, Friberg B, Andréasson L, et al. Effects of phenylpropanolamine on ostial and nasal patency in patients treated for chronic maxillary sinusitis. Acta Otolaryngol 1986; 101:494.
- Aust R, Drettner B, Falck B. Studies of the effect of peroral fenylpropanolamin on the functional size of the human maxillary ostium. Acta Otolaryngol 1979; 88:455.
- MCLAURIN JW, SHIPMAN WF, ROSEDALE R Jr. Oral decongestants. A double blind comparison study of the effectiveness of four sympathomimetic drugs: objective and subjective. Laryngoscope 1961; 71:54.
- Ziment I. Management of respiratory problems in the aged. J Am Geriatr Soc 1982; 30:S36.
- Hwang PH. A 51-year-old woman with acute onset of facial pressure, rhinorrhea, and tooth pain: review of acute rhinosinusitis. JAMA 2009; 301:1798.
- Falagas ME, Giannopoulou KP, Vardakas KZ, et al. Comparison of antibiotics with placebo for treatment of acute sinusitis: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2008; 8:543.
- de Ferranti SD, Ioannidis JP, Lau J, et al. Are amoxycillin and folate inhibitors as effective as other antibiotics for acute sinusitis? A meta-analysis. BMJ 1998; 317:632.
- Lemiengre MB, van Driel ML, Merenstein D, et al. Antibiotics for clinically diagnosed acute rhinosinusitis in adults. Cochrane Database Syst Rev 2012; 10:CD006089.
- Garbutt JM, Banister C, Spitznagel E, Piccirillo JF. Amoxicillin for acute rhinosinusitis: a randomized controlled trial. JAMA 2012; 307:685.
- Young J, De Sutter A, Merenstein D, et al. Antibiotics for adults with clinically diagnosed acute rhinosinusitis: a meta-analysis of individual patient data. Lancet 2008; 371:908.
- Ahovuo-Saloranta A, Borisenko OV, Kovanen N, et al. Antibiotics for acute maxillary sinusitis. Cochrane Database Syst Rev 2008; :CD000243.
- de Bock GH, Dekker FW, Stolk J, et al. Antimicrobial treatment in acute maxillary sinusitis: a meta-analysis. J Clin Epidemiol 1997; 50:881.
- Karageorgopoulos DE, Giannopoulou KP, Grammatikos AP, et al. Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials. CMAJ 2008; 178:845.
- Piccirillo JF, Mager DE, Frisse ME, et al. Impact of first-line vs second-line antibiotics for the treatment of acute uncomplicated sinusitis. JAMA 2001; 286:1849.
- Anon JB, Jacobs MR, Poole MD, et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004; 130:1.
- Wald ER. Staphylococcus aureus: is it a pathogen of acute bacterial sinusitis in children and adults? Clin Infect Dis 2012; 54:826.
- Arrieta JR, Galgano AS, Sakano E, et al. Moxifloxacin vs amoxicillin/clavulanate in the treatment of acute sinusitis. Am J Otolaryngol 2007; 28:78.
- Falagas ME, Karageorgopoulos DE, Grammatikos AP, Matthaiou DK. Effectiveness and safety of short vs. long duration of antibiotic therapy for acute bacterial sinusitis: a meta-analysis of randomized trials. Br J Clin Pharmacol 2009; 67:161.
- Wald ER, Chiponis D, Ledesma-Medina J. Comparative effectiveness of amoxicillin and amoxicillin-clavulanate potassium in acute paranasal sinus infections in children: a double-blind, placebo-controlled trial. Pediatrics 1986; 77:795.
- Venekamp RP, Thompson MJ, Hayward G, et al. Systemic corticosteroids for acute sinusitis. Cochrane Database Syst Rev 2014; 3:CD008115.
- Venekamp RP, Thompson MJ, Rovers MM. Systemic corticosteroid therapy for acute sinusitis. JAMA 2015; 313:1258.
- Venekamp RP, Bonten MJ, Rovers MM, et al. Systemic corticosteroid monotherapy for clinically diagnosed acute rhinosinusitis: a randomized controlled trial. CMAJ 2012; 184:E751.
- Ariza H, Rojas R, Johnson P, et al. Eradication of common pathogens at days 2, 3 and 4 of moxifloxacin therapy in patients with acute bacterial sinusitis. BMC Ear Nose Throat Disord 2006; 6:8.
- Anon JB, Paglia M, Xiang J, et al. Serial sinus aspirate samples during high-dose, short-course levofloxacin treatment of acute maxillary sinusitis. Diagn Microbiol Infect Dis 2007; 57:105.
- Ambrose PG, Anon JB, Owen JS, et al. Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis. Clin Infect Dis 2004; 38:1513.